1689 results about "Biologic Agents" patented technology

A prosthetic screw system that includes a prosthetic screw for at least partial insertion into a bone and / or cartilage. The prosthetic screw includes a head and a lower portion connected to the head. The prosthetic screw system also includes a set of head-pieces that can be connected to the head of the prosthetic screw. The head-pieces have differing configurations that are designed to be connected to different types of components of a prosthetic system. The universal connection arrangement between the prosthetic screw and the set of head-pieces enables the prosthetic screw to be customized for connection with a variety of components of a prosthetic system. The head-pieces can alternatively or additionally include a mechanical and / or electrical mechanism that provides one or more substances (e.g., medicine and / or other biological agent, etc.) and / or electrostimulation to a surgical site.

The present invention provides a flowable composition suitable for use as a controlled release implant. The flowable composition can be administered into the ocular region of a mammal. The composition includes: (a) a biodegradable, biocompatible thermoplastic polymer that is at least substantially insoluble in aqueous medium, water or body fluid; (b) a biological agent, a metabolite thereof, a biological agently acceptable salt thereof, or a prodrug thereof; and (c) a biocompatible organic liquid, at standard temperature and pressure, in which the thermoplastic polymer is soluble. The present invention also provides methods of medical treatment that include administering the flowable composition into the ocular region of a mammal.

A safe and effective treatment to curtail and cure autism spectrum disorders has been described in this invention using insulin, IGF-1, with multiple known adjuvant therapeutic agents, as well as other pharmaceutical, biochemical, nurticeuticals, and biological agents or compounds delivered through the olfactory mucosal region of the nose and external auditory meatus.

Chemical and biological detector systems, devices and apparatus. Such devices may be portable and wearable, such as badges, that are analyte-general, rather than analyte-specific, and which provide an optimal way to notify and protect personnel against known and unknown airborne chemical and biological hazards. The devices of the present invention are advantageously low-cost, have low-power requirements, may be wearable and are designed to detect and alarm to a general chemical and biological threat. A sensor device of the present invention in one embodiment includes two or more sensor devices, a processing module coupled to each of the sensor devices and configured to process signals received from each of the two or more sensor devices to determine an environmental state; and a communication module that communicates information about the environmental state to a user.

A stent that is adapted for introduction into a body passageway and which releases at least one biological agent after being inserted in the body passageway. The release of the at least one biological agent can be a controlled release via molecular diffusion through a non-porous polymer layer.

Compositions and methods for enhancing delivery of molecules, e.g. biological agents, into cells are described. The composition is a conjugate of the biological agent, preferably a nucleic acid analog having a substantially uncharged backbone, covalently linked to a peptide transporter moiety as described. Conjugation of the peptide transporter to a substantially uncharged nucleic acid analog, such as a morpholino oligomer, is also shown to enhance binding of the oligomer to its target sequence and enhance antisense activity.

Disclosed are mixtures and compositions for controlling invertebrate pests relating to combinations comprising (a) 3-bromo-N-[4-chloro-2-methyl-6-[(methylamino)carbonyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide, and its N-oxides, and suitable salts thereof and a component (b) wherein the component (b) is at least one compound or agent selected from neonicotinoids, cholinesterase inhibitors, sodium channel modulators, chitin synthesis inhibitors, ecdysone agonists, lipid biosynthesis inhibitors, macrocyclic lactones, GABA-regulated chloride channel blockers, juvenile hormone mimics, ryanodine receptor ligands, octopamine receptor ligands, mitochondrial electron transport inhibitors, nereistoxin analogs, pyridalyl, flonicamid, pymetrozine, dieldrin, metaflumizone, biological agents, and suitable salts of the foregoing. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a mixture or composition of the invention.

The current invention discloses a method for treating infracted / ischemic injury to a myocardium by injecting a substance into the myocardium. The injected substance helps to prevent negative adaptive remodeling by providing mechanical reinforcement or mechanical reinforcement combined with biological therapy. A number of substances for injection are disclosed, including multi component substances such as platelet gel, and other substances. The substances disclosed may contain additives to augment / enhance the desired effects of the injection. The invention also discloses devices used to inject the substances. The devices can include means for ensuring needles do not penetrate beyond a desired depth into the myocardium. The devices can also include needles having multiple lumens such that the components of the platelet gel will be combined at the injection site and begin polymerization in the myocardium.

A composite biological agent with ternary microorganism for composting process of agricultural waste is composed of a composite biological agent I, a composite biological agent II, and a composite biological agent III, which is characterized in that the composite biological agent I is composed of bacillus, actinomycetes, microzyme and lactobacillus, the composite biological agent II is composed of trichoderma, ergillus, penicillium and trametes versicolor, and the composite biological agent III is composed of photosynthetic bacterium, azotobacter, phosphorus bacteria, and silicate bacterium. 30-60% composite biological agent I, 30-60% composite biological agent II, 10-20% composite biological agent III are mixed or applied to the process of composting process of agricultural waste in phases. Each component ratio and recruitment of biological agents can be both properly adjusted with different dung materials and dung purpose, thereby achieving purpose of using microorganism resources efficiently and raising fermentation efficiency.

The present invention comprises methods and compositions for treating solid surfaces having antimicrobial and biocidal properties. Such surfaces are capable of controlling or killing a broad spectrum of biological agents, including viruses, bacteria and other microbial agents in solids, liquids or gases that subsequently contact the treated surface.

Sequence-specific nucleic acid hybridization assays are used for the detection of specific genetic sequences as indicators of genetic anomalies, mutations, and disease propensity. In addition, they are used for the detection of various biological agents and infectious pathogens. Because a complementary probe or nucleic acid sequence is required to detect a sequence of interest in a hybridization-based assay, nucleic acid sequencing techniques can rapidly determine the specific probe sequence being used for detection. This allows reverse engineered assays to be produced rapidly. In addition, it enables the circumvention of hybridization-based assays for biological agent or infectious pathogen detection by providing the information necessary to create or alter nucleic acid sequences to produce false positives or false negatives. The present invention provides methods and compositions for inhibiting the identification of specific detection sequences. More specifically, the invention provides masking sequences that mask the identity of specific detection sequences.

The present invention provides a flowable composition suitable for use as a controlled release implant. The composition includes: (a) a biodegradable, biocompatible thermoplastic polymer that is at least substantially insoluble in aqueous medium, water or body fluid; (b) a cell-cycle dependent biological agent, a schedule-dependent biological agent, a metabolite thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof; and (c) a biocompatible organic liquid, at standard temperature and pressure, in which the thermoplastic polymer is soluble. The present invention also provides a method of treating cancer in a mammal. The present invention also provides a method of blocking, impeding, or otherwise interfering with cell cycle progression at the G1-phase, G1 / S interphase, S-phase, G2 / M interface or M-phase of the cell cycle in a mammal. The methods includes administering to a mammal an effective amount of a flowable composition of the present invention.

The invention provides surgical devices that provide access to the sub-retinal space using delicate traction to hold the sensory retina to create and maintain a patent sub-retinal space of sufficient size to introduce and perform treatments on the eye. Such treatments may include the introduction of illumination or imaging agents or tools, surgical tools, the infusion of pharmaceutical or biological agents, and the placement of grafts, transplants or implants and the closure of the site through the delivery of a sealant.

The invention is directed to methods and compositions for preparing matrices for controlled delivery of at least one therapeutic or biological agent to a target site in a subject. This is accomplished using nanoparticles coupled to the therapeutic or biological agent that are incorporated within the matrix or reacted on the surface of the matrix.

The invention is a system and method for handling items to be shipped that securely verifies the sender. The invention makes use of pre-printed, unique, labels which are affixed by hand or machine to items to be mailed or shipped. These labels are packaged and distributed in groups. The groups of labels can be sold or freely distributed. Each person or organization that originates shipments is assigned a unique customer account number and their identity is authenticated when this account is created. The group number for a group of labels is linked to a customer account prior to the use of any of the labels from the group. The linking can be done at the time of sale or distribution of the group of labels, or after the sale or distribution thereof. Post-sale linking of a group of labels to a customer account can be done over the phone or through a web-site. The invention overcomes limitations in the prior art by creating a method for authenticating the sender of each item without requiring the use of a computer, printer, postage machine, or any other specialized hardware by the sender. The unique label identifiers are stored in a database that is used to ensure that each label that can be used only once. The invention is suitable for bulk mail processing and individual mail items. The invention provides a method for making selective use of specialized handling equipment, including equipment to irradiate the mail to destroy biological agents.

A method for enhancing the uptake of a therapeutic biological agent by treated cells. A low-power, unfocused field of acoustic energy is directed at the treated cells after the delivery of the therapeutic agent to the treated cells. A related method for stimulating either neural cells or cells in a cell culture. A portable sized device provides the field, and may include either an array of emitters or a scanable emitter.

The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed are four hybridoma cell lines, each of which produces a monoclonal antibody recognizing extracellular domains of prostate specific membrane antigens of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.

A method of evaluating drug efficacy of experimental pharmaceutical agents or biological agents proposed for the treatment of arterial plaque burden is described herein. Arterial plaque from a first appendage is removed and analyzed for the content of one or more markers. One or more test pharmaceutical agent or biological agent alone or in combination are administered to the patient for a specified period of time equal to a period of time after which it is supposed that a marker level will have changed in response to the drug. Arterial plaque is then removed from a second appendage and analyzed for the same marker or markers as the first plaque tissue in order to determine whether the test pharmaceutical agent or biological agent was efficacious in altering the production of the marker in the patient.

Asymmetric bifunctional silyl (ABS) monomers comprising covalently linked pharmaceutical, chemical and biological agents are described. These agents can also be covalently bound via the silyl group to delivery vehicles for delivering the agents to desired targets or areas. Also described are delivery vehicles which contain ABS monomers comprising covalently linked agents and to vehicles that are covalently linked to the ABS monomers. The silyl modifications described herein can modify properties of the agents and vehicles, thereby providing desired solubility, stability, hydrophobicity and targeting.

The invention discloses an enteric-solubility multilayer encysted bacterium microcapsule and making method in the biological agent technical domain, which is characterized by the following: adopting sodium alginate, calcium chloride and chitose as clad material of microcapsule; making lactic acid bacteria or bifidobacteria as core-clad material; proceeding ionic exchange for sodium alginate and calcium chloride; forming second clad on the surface of calcium alginate through different isoelectric points of calcium alginate and chitose; freezing at low temperature to obtain the product.

The present invention provides a catch and snare system for an unmanned aerial vehicle comprising: (a) a detection system, (b) a deployment system in communication with the detection system, (c) a capture system placed at an interference position by the deployment system, wherein the capture system comprises a net, a plurality of foam deploying canisters attached to the net for deploying foam, and at least one canister for deploying a decelerating parachute attached to the net, wherein the foam prevents the release of chemical or biological agents from the captured unmanned aerial vehicle, and (d) a descent system to bring the capture system and a captured unmanned aerial vehicle back to earth.

Embodiments of the invention relate to a curable nucleus pulposus implant having water absorption and swelling capabilities, compositions for producing the curable nucleus pulposus implants, and methods of using the curable nucleus pulposus implants. The curable nucleus pulposus implant can be created from a polymer blend composition comprising a ratio of a curable material and at least one hydrophilic polymer. The resulting polymer blend composition may be used to generate curable nucleus pulposus implants to treat a number of disease and / or disorders, such as herniated discs. The curable nucleus pulposus implants may further contain polyelectrolytes and elastomer compounds, as well as pharmacological and biological agents.

A system and related methods for maintaining the patentcy of the ureter comprising a pusher tube having a pusher tube lumen and an inflate lumen disposed within a wall of the pusher tube and a urinary stent having a proximal and distal portions with an elongated body portion therebetween configured to fit the ureter of the patient and defining a lumen. The system further includes an end-effector that may comprise an inflatable balloon positioned at the proximal portion of the urinary stent for retaining the proximal portion in the urinary bladder. At the distal portion, a retention end-piece is positioned for retaining the distal portion of the stent in the renal pelvis. The end-effector and the retention end-piece of the stent maintain the elongated body portion in situ. The end-effector may also include an inflatable balloon and may contain pharmaceutical or biologic agents for controlled release into the bladder.